OneSource targets growth driven by demand for diabetes care and weight loss drugs, says CEO Neeraj Sharma
Subscribe to enjoy similar stories. Drugs used to treat diabetes and obesity, or GLP-1 (Glucagon-like peptide-1), will be a significant growth driver for OneSource Specialty Pharma, CEO and MD Neeraj Sharma said. On the other hand, biologics is a long-term play for the company, as the business has a long gestation period.
OneSource is the contract development and manufacturing (CDMO) arm of Strides Pharma and is set to be listed next month. “In generic GLP-1s, we have a pioneering strategy. We were the first to enter and today we are the only ones offering complete end-to-end solutions," Sharma told Mint in an interview.
GLP-1 drugs like Danish drugmaker Novo Nordisk’s semaglutide have been game changers in obesity treatment, with demand across the globe soaring. With several GLP-1 drugs going off patent in the next few years, OneSource is poised to see big growth in the generic GLP-1 space. OneSource has a formidable position in the generic GLP-1s because they offer end-to-end services including formulation and assembly into the device.
GLP-1 drugs are mostly used though pens. “The most complex part of the whole value chain is to assemble that pen," Sharma said. “We are able to handle multiple types of pen devices," he added.
Drug-device combinations, like the GLP-1 pens, is one business under OneSource Specialty Pharma. The firm also has a biologics business, a sterile injectables business, and a soft-gelatin capsules business. Arun Kumar-led Strides Pharma Science, which has a market cap of ₹6,507 crore, announced the creation of OneSource Specialty Pharma, a specialty pharma pure-play CDMO player in September 2023—integrating Stelis Biopharma Ltd, Strides' Oral Technologies (soft gelatin capsules) and SteriScience’s
. Read more on livemint.com
